Literature DB >> 16124984

Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients.

H-X Xu1, M-D Lu, X-Y Xie, X-Y Yin, M Kuang, J-W Chen, Z-F Xu, G-J Liu.   

Abstract

AIM: To identify prognostic factors for long-term outcome for patients with hepatocellular carcinoma (HCC) after percutaneous microwave or radiofrequency ablation.
MATERIALS AND METHODS: In total, 137 consecutive patients with HCC underwent microwave or radiofrequency ablation with curative intent; 16 possible prognostic factors were evaluated for their association with overall survival (OS) and disease-free survival (DFS) using univariate and multivariate analysis.
RESULTS: The median OS and DFS were 27.0 months and 8.2 months, respectively. OS rates for all patients at 1, 2, 3, 4 and 5 years were 73.9%, 52.1%, 42.8%, 26.2% and 20.1%, respectively. DFS rates at 1, 2, 3 and 4 years were 38.1%, 21.9%, 18.8%, and 14.1%, respectively. Pretreatment serum alpha-fetoprotein (AFP) >200 ng/ml, pretreatment serum albumin <or=35 g/dl, liver function Child's class C and incomplete ablation were found to be significant predictors for OS by univariate analysis. Using multivariate analysis, incomplete ablation was identified to be the most significant independent predictor for OS. Other independent predictors for OS were serum albumin level, serum AFP level and Child-Pugh classification. Recurrence after hepatectomy and prothrombin time >14 s were identified to be significant predictors for DFS by univariate analysis, and the former was the only independent predictor for DFS by multivariate analysis.
CONCLUSION: Prognosis for patients with HCC after thermal ablation with curative intent was determined by treatment response to ablation, pretreatment serum AFP, and liver function reserve. Tumour response to treatment was the most predictive factor for long-term survival and was related to tumour size, thus careful selection of patients for ablation therapy is recommended.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16124984     DOI: 10.1016/j.crad.2005.04.009

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  36 in total

1.  Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study.

Authors:  Ming-De Lu; Hui-Xiong Xu; Xiao-Yan Xie; Xiao-Yu Yin; Jun-Wei Chen; Ming Kuang; Zuo-Feng Xu; Guang-Jian Liu; Yan-Lin Zheng
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

Review 2.  Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.

Authors:  Lili Gu; Huiling Liu; Linlin Fan; Yuanjun Lv; Zhuang Cui; Yan Luo; Yuanyuan Liu; Guang Li; Changping Li; Jun Ma
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

3.  Hepatocellular carcinoma specific graded prognostic assessment can predict outcomes for patients with brain metastases from hepatocellular carcinoma.

Authors:  Seungtaek Lim; Soohyeon Lee; Jae Yun Lim; Ji Soo Park; Jin Sil Seong; Won Seok Chang; Kwang-Hyub Han; Hye Jin Choi
Journal:  J Neurooncol       Date:  2014-07-26       Impact factor: 4.130

Review 4.  The current status of contrast-enhanced ultrasound in China.

Authors:  Hui-Xiong Xu; Ming-De Lu
Journal:  J Med Ultrason (2001)       Date:  2010-04-21       Impact factor: 1.314

5.  Era of diagnostic and interventional ultrasound.

Authors:  Hui-Xiong Xu
Journal:  World J Radiol       Date:  2011-05-28

6.  Comparison of 3D ultrasound and magnetic resonance imaging for microwave ablation in the canine splenomegaly model.

Authors:  Lin Sheng; Jialiang Li; Jibing Chen; Ping Liang; Baowei Dong
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-07-03       Impact factor: 2.924

7.  Microwave ablation energy delivery: influence of power pulsing on ablation results in an ex vivo and in vivo liver model.

Authors:  Mariajose Bedoya; Alejandro Muñoz del Rio; Jason Chiang; Christopher L Brace
Journal:  Med Phys       Date:  2014-12       Impact factor: 4.071

Review 8.  Microwave ablation of hepatic malignancy.

Authors:  Meghan G Lubner; Christopher L Brace; Tim J Ziemlewicz; J Louis Hinshaw; Fred T Lee
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 9.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

10.  Hepatocellular carcinoma after ablation: the imaging follow-up scheme.

Authors:  Lin-Na Liu; Hui-Xiong Xu; Yi-Feng Zhang; Jun-Mei Xu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.